8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
Vir Biotechnology Inc. (VIR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 2,380,715 | $14,355,711 | 0.29% | |
| 2. | Balyasny Asset Management Dmitry Balyasny | 1,368,474 | $8,251,898 | 0.01% | |
| 3. | Hudson Bay Capital Management Sander Gerber | 1,325,000 | $7,989,750 | +46% | 0.03% |
| 4. | Millennium Management Israel Englander | 1,002,606 | $6,045,714 | -29% | 0% |
| 5. | GordonMD Global Investments Craig Gordon | 930,317 | $5,609,812 | 4.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.73 | 2,500 | $56,815.50 | 10,000 | 2023-03-01 | Filing | |
| $24.96 | 2,500 | $62,395.50 | 7,500 | 2023-01-05 | Filing | |
| $25.25 | 2,500 | $63,136.25 | 5,000 | 2023-01-04 | Filing | |
| $25.60 | 2,500 | $63,992.50 | 2,500 | 2023-01-03 | Filing | |
| $43.39 | 12 | $499.85 | 12 | 2021-11-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.16 | 72,559 | $664,350.20 | 948,145 | 2026-04-06 | Filing | |
| $9.07 | 22,000 | $199,617.00 | 1,100,391 | 2026-04-01 | Filing | |
| $9.12 | 7,711 | $70,324.32 | 61,902 | 2026-03-23 | Filing | |
| $9.98 | 200 | $1,996.00 | 1,122,391 | 2026-03-02 | Filing | |
| $9.50 | 21,800 | $207,185.02 | 1,122,591 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 113,028 | $1,012,731 | 0.01% | |
| 2. | 32,038 | $287,060 | 0.01% | |
| 3. | 25,319 | $229,390 | 0% | |
| 4. | 16,896 | $151,388 | 0% | |
| 5. | 10,073 | $90,254 | 0% |
News See All
Vir Biotechnology (VIR) Leading with Its BiTEs Therapy
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Vir Biotechnology's conference call to discuss the company's VIR-5500 Strategic Collaboration with Astellas and Positive Phase I Data, and 2025 financial results...
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2025 Financial Results and Corporate Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology's Second Quarter 2025 Financial Results and Corporate Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology's First Quarter 2025 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Why These 15 Stocks Are Skyrocketing in 2025
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript
Operator: [Call starts abruptly] …Vir's Third Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Hedge Fund Resource Center